29748886,29724167,29743050,29747595,29733122,29736626,29733814,29726378,29726385,29726384,29726386,29726379,29726382,29726383,29750753,29746316,29750749,29750751,29750752,29750750,29749510[uid] - Search Results

1

Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients.

Cui C, Lian B, Zhou L, Song X, Zhang X, Wu D, Chi Z, Si L, Sheng X, Kong Y, Tang B, Mao L, Wang X, Li S, Dai J, Yan X, Bai X, Balch CM, Guo J. Cui C, et al. Ann Surg Oncol. 2018 Aug;25(8):2184-2192. doi: 10.1245/s10434-018-6503-9. Epub 2018 May 10. Ann Surg Oncol. 2018. PMID: 29748886

2

Vemurafenib in Chinese patients with BRAF^V600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.

Si L, Zhang X, Xu Z, Jiang Q, Bu L, Wang X, Mao L, Zhang W, Richie N, Guo J. Si L, et al. BMC Cancer. 2018 May 3;18(1):520. doi: 10.1186/s12885-018-4336-3. BMC Cancer. 2018. PMID: 29724167 Free PMC article. Clinical Trial.

3

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.

McDonald MA, Sanghvi P, Bykowski J, Daniels GA. McDonald MA, et al. BMC Cancer. 2018 May 9;18(1):549. doi: 10.1186/s12885-018-4470-y. BMC Cancer. 2018. PMID: 29743050 Free PMC article. Review.

4

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

Guida M, Tommasi S, Strippoli S, Natalicchio MI, De Summa S, Pinto R, Cramarossa A, Albano A, Pisconti S, Aieta M, Ridolfi R, Azzariti A, Guida G, Lorusso V, Colucci G. Guida M, et al. BMC Cancer. 2018 May 10;18(1):552. doi: 10.1186/s12885-018-4479-2. BMC Cancer. 2018. PMID: 29747595 Free PMC article. Clinical Trial.

5

Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors.

Fujisawa Y. Fujisawa Y. Br J Dermatol. 2018 Jul;179(1):224-225. doi: 10.1111/bjd.16689. Epub 2018 May 7. Br J Dermatol. 2018. PMID: 29733122 No abstract available.

6

Regional therapies for locoregionally advanced and unresectable melanoma.

Weitman ES, Zager JS. Weitman ES, et al. Clin Exp Metastasis. 2018 Aug;35(5-6):495-502. doi: 10.1007/s10585-018-9890-1. Epub 2018 May 8. Clin Exp Metastasis. 2018. PMID: 29736626 Review.

7

Physician Skin Checks before the Diagnosis of Melanoma Correlate with Tumor Characteristics.

Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Green AC, Neale RE, Whiteman DC; QSkin Study. Olsen CM, et al. J Invest Dermatol. 2018 Oct;138(10):2288-2291. doi: 10.1016/j.jid.2018.04.017. Epub 2018 May 5. J Invest Dermatol. 2018. PMID: 29733814 Free article. No abstract available.

8

Anti-PD-1 antibody treatment for melanoma.

Ribas A, Kirkwood JM, Flaherty KT. Ribas A, et al. Lancet Oncol. 2018 May;19(5):e219. doi: 10.1016/S1470-2045(18)30202-X. Lancet Oncol. 2018. PMID: 29726378 No abstract available.

9

Body-mass index and metastatic melanoma outcomes.

Nabi H, Guertin JR, Talbot D, Diorio C. Nabi H, et al. Lancet Oncol. 2018 May;19(5):e226. doi: 10.1016/S1470-2045(18)30287-0. Lancet Oncol. 2018. PMID: 29726385 No abstract available.

10

Body-mass index and metastatic melanoma outcomes.

Lennon H, Badrick E, Sperrin M, Renehan AG. Lennon H, et al. Lancet Oncol. 2018 May;19(5):e225. doi: 10.1016/S1470-2045(18)30277-8. Lancet Oncol. 2018. PMID: 29726384 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21 results

Search Page